In the chemotherapy group, AML patients with high Wnt2B expression had significantly shorter EFS and OS compared with low Wnt2B expressers (all P < .05, Figure 2A,B); high Wnt11 expressers had significantly shorter EFS and OS than low expressers (all P < .001, Figure 2E,F), whereas high Wnt10A expression had favourable effect on OS (P = .043, Figure 2D). Here, WNT2B is linked to acute myeloid leukemia.